News

Symbiance delivers data solutions for pharmaceutical and biotechnology companies. Symbiance includes a clinical data management unit, biostatistical analysis, and SAS programming divisions supporting Phase I through IV clinical

Soligenix has completed a Phase 1A clinical trial of RiVax which showed that the immunogen was safe and induced antibodies anticipated to protect humans from ricin exposure. Further,

Under the agreement, Unity/MCC is expected to have all distribution and marketing rights in the US, and will increase their market share in new presses for Novartis and

In the collaboration, RBM will discover and also confirm plasma protein biomarker candidates identified from the multicenter Biomarkers for SMA (BforSMA) clinical study sponsored by the SMA Foundation

In the study, the company will investigate the safety and efficacy and pharmacokinetics of Resminostat in conjunction with Folfiri versus Folfiri alone in the control arm. In the

Under the contract, Evotec is expected to use its Screening Platform and proprietary GPCR modeling software for identifying and validating novel modulators against various targets selected by Takeda

Under the pact, both the companies have decided to establish a joint venture, Amrutanjan Pharmaessense Ltd (Pharmaessense). Amrutanjan’s fine chemical division Pharmaessense provides value added servics to several

TC-5619 is a highly selective alpha7 neuronal nicotinic receptor modulator, which is subject to licence by Targacept’s strategic partner AstraZeneca. In the trial, TC-5619 met the primary efficacy

The Phase 1/2 trial is an open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN 701. In the study, BMN 701 will